PROVE-IT was a sensational study. This study was funded by makers of Pravastatin. Because the pravastatin 40mg proved inferior to Atorva 80mg in patients with ACS; so the Prava company felt humiliated and removed the product from the market. A great loss to the profession because there were some exclusive indications of Prava like following organ transplantation, where most statins had adverse drug-drug interactions unlike Prava. Prava is an impressive molecule with wealth of data and large RCTs. The company should have maintained their self-image and should have continued with Prava at least for its exclusive indications.
PROVE-IT was a sensational study. This study was funded by makers of Pravastatin. Because the pravastatin 40mg proved inferior to Atorva 80mg in patients with ACS; so the Prava company felt humiliated and removed the product from the market. A great loss to the profession because there were some exclusive indications of Prava like following organ transplantation, where most statins had adverse drug-drug interactions unlike Prava. Prava is an impressive molecule with wealth of data and large RCTs. The company should have maintained their self-image and should have continued with Prava at least for its exclusive indications.